

# 1 Unequal Recovery in Colorectal Cancer Screening

## 2 Following the COVID-19 Pandemic

### 3 *A Comparative Microsimulation Analysis*

4  
5 *Pedro Nascimento de Lima<sup>1</sup>, Rosita van den Puttelaar<sup>2</sup>, Anne I. Hahn<sup>3</sup>, Matthias Harlass<sup>2</sup>,*  
6 *Nicholson Collier<sup>4</sup>, Jonathan Ozik<sup>4</sup>, Ann G. Zauber<sup>3</sup>, Iris Lansdorp-Vogelaar<sup>2</sup>, Carolyn M. Rutter<sup>5</sup>*

#### 7 8 9 **Abstract**

10 *The aftermath of the initial phase of the COVID-19 pandemic may contribute to the widening*  
11 *of disparities in access to colorectal cancer (CRC) screening due to differential disruptions to*  
12 *CRC screening. This comparative microsimulation analysis uses two CISNET CRC models to*  
13 *simulate the impact of ongoing screening disruptions induced by the COVID-19 pandemic on*  
14 *long-term CRC outcomes. We evaluate three channels through which screening was*  
15 *disrupted: delays in screening, regimen switching, and screening discontinuation. The impact*  
16 *of these disruptions on long-term colorectal cancer (CRC) outcomes was measured by the*  
17 *number of Life-years lost due to CRC screening disruptions compared to a scenario without*  
18 *any disruptions. While short-term delays in screening of 3-18 months are predicted to result*  
19 *in minor life-years loss, discontinuing screening could result in much more significant*  
20 *reductions in the expected benefits of screening. These results demonstrate that unequal*  
21 *recovery of screening following the pandemic can widen disparities in colorectal cancer*  
22 *outcomes and emphasize the importance of ensuring equitable recovery to screening*  
23 *following the pandemic.*

24  
25  
<sup>1</sup> Engineering and Applied Sciences Department, RAND Corporation, Santa Monica, California, USA

<sup>2</sup> Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, Netherlands

<sup>3</sup> Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA

<sup>4</sup> Decision and Infrastructure Sciences Division, Argonne National Laboratory, Lemont, Illinois, USA

<sup>5</sup> Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA

## 26 **Introduction**

27 The novel SARS-Cov-2 (COVID-19) pandemic has resulted in major health consequences  
28 across the globe. In addition to the over 1 million COVID-19 deaths in the United States,<sup>1</sup>  
29 the pandemic has also contributed to steep declines in cancer screening, most notably in  
30 the early phases of the pandemic due to government-mandated shutdowns of non-  
31 emergency medical services.<sup>2</sup> It is estimated that colorectal cancer screening (CRC)  
32 decreased by 85% in the United States during the early phase of the pandemic, from March  
33 through April 2020.<sup>3</sup> The pandemic continues to affect CRC screening and diagnosis  
34 through staff shortages that reduce capacity at gastroenterology clinics and patient  
35 hesitancy to seek care.<sup>4, 5</sup> Despite cancer screening reopening efforts, CRC screening has  
36 not yet returned to pre-pandemic levels.<sup>6</sup>

37 CRC remains the second-leading cause of cancer deaths in the United States, with  
38 approximately 151,030 new cases and 52,580 deaths estimated in 2022.<sup>7</sup> There is clear  
39 evidence that screening has a major impact on reducing the burden of CRC,<sup>8,9</sup> and that it  
40 is cost-effective.<sup>10, 11</sup> The current United States Preventive Task Force (USPSTF) report  
41 recommends multiple screening options, including annual fecal immunochemical tests  
42 (FIT) and colonoscopy every ten years for average-risk individuals.<sup>12</sup> However, CRC  
43 screening uptake was of concern even before the pandemic, with CRC screening rates well  
44 below the goal of 70.5% for Healthy People 2020 and the National Colorectal Cancer  
45 Roundtable goal of 80% by 2018.<sup>13</sup> Low rates of CRC screening have been exacerbated by  
46 the COVID-19 pandemic, and delays in screening will result in delays in diagnosis, stage  
47 progression, and increased CRC mortality.

48 The pandemic may also further exacerbate existing disparities related to screening.  
49 The burden of unemployment and associated loss of access to healthcare care varies across  
50 different racial and ethnic groups.<sup>14</sup> Because of this, the pandemic may contribute to  
51 widening disparities in cancer outcomes. A recent analysis using National Health  
52 Interview Survey (NHIS) data postulated that unemployment was adversely associated  
53 with being up-to-date with screening, with only 16.7% of unemployed individuals

54 participating in recent CRC screenings, only 48.5% of whom were up-to-date with CRC  
55 screening.<sup>15</sup>

56 The objective of this study is to estimate the impact of ongoing screening and  
57 treatment disruptions induced by the COVID-19 pandemic on long-term CRC outcomes. We  
58 examine twenty-five scenarios that reflect different levels of pre-pandemic adherence to  
59 colonoscopy and FIT screening to assess how unequal recovery in screening may  
60 contribute to widening disparities in CRC lifetime outcomes.

61

## 62 **Methods**

63 This paper uses two independently developed microsimulation models of CRC, CRC-SPIN  
64 and MISCAN-Colon, to estimate the effects of pandemic-induced disruptions in  
65 colonoscopy screening for eight pre-pandemic average-CRC risk population cohorts in the  
66 United States. CRC-SPIN and MISCAN-Colon models are part of the National Cancer  
67 Institute's CISNET consortium and describe the natural history of CRC in an unscreened  
68 population based on the adenoma-carcinoma sequence. Detailed descriptions of these  
69 models and underlying assumptions may be found elsewhere.<sup>10, 16, 17,18</sup> We consider  
70 variations on two commonly-used screening strategies in the USPSTF recommendations  
71 during the onset of the pandemic in March 2020<sup>19</sup>: Decennial colonoscopy from age 50 to  
72 70 and annual FIT tests from age 50 to 75, with diagnostic colonoscopy after a positive FIT.  
73 Supplementary Table 1 presents the operating characteristics assumed for each test.  
74 Individuals with adenomas detected at screening enter adenoma surveillance;  
75 Supplementary Table 2 describes the frequency of surveillance colonoscopies based on  
76 prior test results.

77

## 78 **Cohorts**

79 We simulated eight pre-pandemic population cohorts that represent average-risk  
80 individuals in the United States, defined by both cohort members' age in April 2020 and  
81 their pre-pandemic screening regimens: i) Unscreened 50-year-olds (U50), ii) Unscreened

82 60-year-olds (U60), iii) Colonoscopy screening-adherent 60-year-olds (C60, who received  
83 their first screening colonoscopy at age 50 but have not yet had a colonoscopy at age 60),  
84 iv) FIT screening-adherent 60-year-olds (F60, who performed annual FIT tests from age 50  
85 to 59, v) FIT screening semi-adherent 60-year-olds (f60) – those who received biannual FIT  
86 tests from age 50 to 56, vi) Unscreened 70-year-olds (U70), vii) Colonoscopy screening-  
87 adherent 70-year-olds (C70, who received screening colonoscopies at age 50 and 60), and  
88 viii) FIT screening-adherent 70-year-olds (F70, who performed annual FIT tests from age  
89 50 to 69). We simulated 10 million individuals within each cohort to reduce the stochastic  
90 variability in our runs and to ensure sufficient precision in our estimates. For each cohort,  
91 we simulated three sets of post-pandemic scenarios: no disruption, delays, and no  
92 screening.

93

#### 94 ***Screening Regimens under no Disruption***

95 The *No-disruption* scenarios simulate post-pandemic screening scenarios for each cohort  
96 in the counterfactual scenario where no pandemic-induced screening disruptions  
97 occurred. In No Disruption scenarios, all these cohorts would have been screened during  
98 the pandemic first lockdowns in March 2020. Cohorts with colonoscopy and FIT adherent  
99 individuals (U50, C60, F60 C70, F70) continue to follow guideline-recommended strategies  
100 strictly, with no delays. Cohorts with delayed initiation (U60, U70) begin screening late but  
101 otherwise follow guideline-recommended strategies with no delays but without any  
102 additional screening beyond the usual stopping age. Finally, for the *FIT-semi-adherent 60-*  
103 *year-olds* (f60), we simulate resumption of biannual FIT tests at age 60, continuing to age  
104 75.

105

#### 106 ***Pandemic-Induced disruptions in CRC Screening***

##### 107 *Delays*

108 The pandemic has been shown to affect CRC outcomes through *delays* in screening.  
109 Screening colonoscopy and FIT are assumed to be delayed for a set duration of months

110 starting at the onset of the COVID-19 pandemic in April 2020. Short-term screening delays  
111 may have occurred for a series of reasons. Firstly, elective procedures were postponed  
112 during the first months of the pandemic. The cancellation of elective procedures caused a  
113 sharp decline in CRC screening exams during the initial phase of the pandemic.<sup>20</sup> To  
114 represent the full spectrum of delays caused by the pandemic – either due to cancellation  
115 of elective procedures or disruption in access to health care – we consider three sets of  
116 delays: a 3, 9, or 18-month delay in screening, which we label as *short-term* delays. For  
117 each delay scenario, the delay was applied on the first post-March 2020 screening exam  
118 and carried forward to any subsequent exams.

119 Secondly, the pandemic may have caused *long-term delays* in CRC screening. While  
120 the recovery in screening rates among insured individuals was rapid,<sup>21</sup> the pandemic also  
121 caused a sharp economic recession. The uneven recovery in labor force participation has  
122 potential to cause disparities in access to healthcare in the United States due to  
123 unemployment and discontinuation of health insurance. To examine these longer-term  
124 effects of the pandemic, we consider scenarios where screening is paused for an extended  
125 period. For the 50- and 60-year-old cohorts, we simulated scenarios where screening is  
126 discontinued until the start age of Medicare enrollment (65 years). For 70-year-olds, we  
127 consider a scenario where screening is only resumed at age 75 – 5 years after the pandemic  
128 onset.

129

### 130 *Screening Regimen Switching*

131 The pandemic may also affect CRC behavior via screening *regimen switching* – i.e.,  
132 changing from a colonoscopy screening regimen to one based on FIT tests. There is  
133 evidence that during the pandemic some patients switched from colonoscopy to FIT<sup>15</sup> to  
134 reduce the need for in-person endoscopy procedures. Considering this possibility, we  
135 model scenarios where individuals who initially participated in a regimen of screening  
136 colonoscopy (C60 and C70) permanently switch from decennial colonoscopy to annual FIT  
137 screening as a boundary case. While one might expect pandemic-induced regimen  
138 switching to be temporary, permanent switching can serve as a boundary case for our

139 analysis – that is, the effect of short-term regimen switching is expected to be lower than  
140 the effect of permanent regimen switching.

141

#### 142 *Screening Discontinuation*

143 We also simulate scenarios where screening is completely discontinued after the  
144 pandemic onset as the most consequential boundary case scenario. While only a small  
145 (unknown) proportion of individuals will discontinue screening after the pandemic, this  
146 scenario serves as an upper bound for the worst possible disruption in CRC screening  
147 following the pandemic.

148

#### 149 *Scenarios*

150 Each of the scenarios simulated in this study results from the combination of a pre-  
151 pandemic population cohort, a no-disruption screening scenario that serves as a  
152 counterfactual, and one or more screening disruptions (i.e., switching to FIT screening  
153 occurred in tandem with short-term delays). Table 1 lists those combinations and the  
154 scenario labels used in this analysis. We code our scenarios as *[pre-pandemic screening*  
155 *cohort] | [post pandemic disruptions]*.

156

157

158

159

**Table 1. Study Cohorts and Scenarios**

Cohort	No-disruption Counterfactual	CRC Screening Disruption Scenario	
		Description	Label
Unscreened 50-year-olds (U50)	Decennial COL from age 50 to 70	Short-term delays of [d] months*	U50   C[d]m
		Long-term delay (COL at age 65 and 75)	U50   C@65
Unscreened 60-year-olds (U60)	Annual FIT from age 50 to 75	Short-term delays*	U50   F[d]m
		Decennial COL from age 60 to 70	Short-term delays*
COL-adherent 60-year-olds (C60)	Annual FIT from age 60 to 75	Long-term delay (COL at age 65 and 75)	U60   C@65
		Short-term delays*	U60   F[d]m
FIT-adherent 60-year-olds (F60)	Decennial COL from age 50 to 70	Short-term delays*	C60   C[d]m
		Switch to annual FIT and Short-term delays	C60   F[d]m
		Long-term delay (COL at age 65 and 75)	C60   C@65
FIT-semi-adherent 60-year-olds (f60)	Annual FIT from age 50 to 75	Discontinue screening	C60   U
		Short-term delays*	F60   F[d]m
Unscreened 70-year-olds (U70)	Biannual FIT from age 50 to 56, annual FIT from age 60 to 75	Discontinue screening	F60   U
		Short-term delays*	f60   F[d]m
COL-adherent 70-year-olds (C70)	COL at age 70	Discontinue screening	f60   U
		Short-term delays*	U70   C[d]m
FIT-adherent 70-year-olds (F70)	Annual FIT from age 70 to 75	Long-term delay (COL at age 75)	U70   C@75
		Short-term delays	U70   F[d]m
Unscreened 70-year-olds (U70)	Decennial COL from age 50 to 70	Short-term delays*	C70   C[d]m
		Switch to annual FIT and Short-term delays	C70   F[d]m
		Long-term delay	C70   C@75
		Perform COL at age 75	C70   U
FIT-adherent 70-year-olds (F70)	Annual FIT from age 50 to 75	Discontinue screening	C70   U
		Short-term delays*	F70   F[d]m
FIT-adherent 70-year-olds (F70)	Annual FIT from age 50 to 75	Discontinue screening	F70   U

*Notes: This table presents the scenarios considered in this study. Each scenario corresponds to a combination of a population cohort, indicated by their age during the first COVID-19 lockdowns (March 2020), a pre-pandemic, and a post-pandemic screening regimen. The scenarios aim to represent possible combinations of screening regimens followed in the United States. The first letter in the scenario code represents screening before the pandemic and the second letter represents screening after the pandemic.*

*\*Delays of 3, 9, and 18 months. Letter d stands for the number of months of delays.*

160

161

## 162 **Outcomes**

163 The primary measure used to assess the benefit of CRC screening programs is the expected  
164 lifetime life-years gained (LYG) from screening. All outcomes in this study correspond to  
165 expected value of life-years across the US population with average CRC risk. This study  
166 investigates the extent to which benefits from screening are expected to be lost due to  
167 pandemic-induced disruptions to CRC screening. Therefore, we calculated the total  
168 number of Life-Years (LY) for each cohort and scenario, including the number of LY under  
169 no screening (LYNS) and the number of LY under no disruptions (LYND). LYNS is  
170 computed by simulating the cohort in the absence of CRC screening and LYND is computed  
171 by simulating the same cohort under an ideal screening scenario where no disruptions to  
172 screening happened, as defined in Table 1.

173 The key outcome estimated in this study is the expected number of LY lost (LYL)  
174 due to disruptions in screening, defined as  $LYL = LYND - LY$ . The hypothetical number of  
175 LY gained (LYG) from screening under no disruptions are  $LYG_{no\ disruption} = LYND - LYNS$ .  
176 Finally, we compute the percentage of life-years gained or lost due to disruption as  
177  $\% LY\ Lost = 100 * LYL / LYG_{no\ disruption}$ . The first outcome measure (LYL) is an absolute  
178 measure of the loss of screening benefit due to pandemic disruptions. The percent LY lost  
179 due to disruptions indicates the share of screening benefit lost due to the pandemic.  
180 Following previous analyses, we present all outcomes as LY per 1,000 individuals or life  
181 days per person. We compute each of those outcomes separately for each model and report  
182 the range of outcomes observed across both models.

183

## 184 **Results**

185 Loss of life due to screening disruptions was the largest for cohorts with severe disruptions  
186 after the pandemic (Figure 1). Aside from not receiving any screening, the worst-case  
187 scenario for the 50-year-old cohort is to postpone screening until age 65 when they become  
188 Medicare eligible. This cohort (scenario U50 | C@65) is expected to lose 104 to 127 LY per  
189 1,000 individuals, and a 38 to 42 percent loss in LYG compared to a no-disruption scenario  
190 where they start screening at age 50 (Supplementary Table 3). Other disruption scenarios




191 are predicted to have minor effects on this cohort. For example, 50-year-olds with  
192 colonoscopy screening delayed by 18 months (scenario U50 | C18m) are expected to  
193 experience a loss of 6 to 7 LY per 1,000 individuals, and a 2 percent loss in LYG from  
194 screening compared to a no-disruption scenario.

195 Similarly, 60-year-olds are expected to incur a substantial reduction in the benefit  
196 of screening if screening is discontinued after the pandemic. Those who started screening  
197 at age 50 and stopped after the pandemic are expected to lose 106 to 124 or 92 to 111 LY  
198 per 1,000 individuals if pursuing a colonoscopy (C60 | U) or a FIT (F60 | U) screening  
199 regimen, respectively. Those who were semi-adherent to FIT screening before the  
200 pandemic and discontinued screening (f60 | U) lose even more life-years – from 143 to 149  
201 LY per 1,000 individuals, or 58 to 69 percent of the benefit of screening. Similarly,  
202 unscreened 60-year-olds who start screening at age 65 (scenario U60 | C@65) are predicted  
203 to lose 42 to 45 LY per 1,000 individuals compared to a scenario where they would have  
204 begun screening at age 60 - , and a 20 to 22 percent loss in LYG from screening due to this  
205 disruption.

206 Switching the screening regimen from colonoscopy to FIT and short-term delays  
207 will cause only a modest reduction in the benefit of screening. For the 60-year-old cohort,  
208 switching from colonoscopy to annual FIT after the pandemic with an 18-month delay is  
209 expected to result in a loss of 9 to 11 LY per 1000 individuals, a 3 to 4 percent loss relative  
210 to a scenario with no change in screening regimen and no delays. Similarly, short-term  
211 delays are predicted to cause minimal decreases in the benefits of the screening program.  
212 A 3-month delay in colonoscopy screening results in a loss of 0 to 2 LY per 1,000 individuals  
213 for the 60-year cohort (scenarios C60 | C3m), whereas a 9- or 18-month delay (C60 | C9m  
214 and C60 | C18m) is expected to result in a loss of 0 to 2 or 0 to 3 LY per 1,000 individuals,  
215 respectively). The worst-case scenario of a 18-month pause starting in March 2020  
216 (scenario C60 | C18m) resulted in a 0 to 1 percent loss of the benefit of screening.

217 **Figure 1.** Screening Benefits lost due to disruptions by Cohort and Scenario



218  
 219 *Notes:* Each dot represents the estimated life-years lost per 1,000 individuals or life-days lost from one model  
 220 under the High Sensitivity Scenario. Results are ordered from highest to lowest reduction in benefit induced  
 221 by the pandemic. Scenarios that result in less than 2 life-days lost per person are omitted from this figure and  
 222 presented in Supplementary Figure 1. Supplementary Figures 2 and 3 show results for a “Low” Colonoscopy  
 223 sensitivity scenario. This figure does not present a counterfactual no-screening scenario for the 50-year-olds.  
 224

225 70-year-olds lose fewer life-years due to screening disruptions but can still be  
226 affected by the pandemic as they are at greater risk for CRC than younger age groups.  
227 When discontinuing screening after the pandemic, 70-year-olds are expected to lose 38 to  
228 87 or 29 to 33 LY per 1,000 individuals due to the pandemic if pursuing a colonoscopy (C70  
229 | U) or FIT (F70 | U) screening regimen, respectively. Unscreened 70-year-olds who only  
230 come back to screening at age 75 (scenario U70 | C@75) are expected to lose 49 to 50 LY  
231 per 1,000 individuals, a 39 to 43 percent reduction in LYG relative to a scenario where they  
232 would have received colonoscopy screening at age 70.

233 70-year-olds who were up to date with their screening and experienced short-term  
234 delays of up to 18 months can expect minimal loss of LY due to pandemic-induced CRC  
235 screening disruptions, even if they switch to FIT tests after the pandemic. Those who  
236 transitioned from colonoscopy to FIT screening at age 70 can expect a reduction of 5 to 7  
237 LY per 1,000 individuals even if a return to FIT screening was delayed by 18 months  
238 (scenario C70 | F18m). This reduction in benefit represents a 2 to 3 percent reduction in  
239 LYG of colonoscopy-only screening.

240

#### 241 *Low-Sensitivity Scenarios*

242 While colonoscopy sensitivity affects the overall benefit of screening, *conditional on*  
243 *colonoscopy sensitivity*, the loss of life-years due to pandemic-induced scenarios is similar  
244 across sensitivity levels. Supplementary Figures 4 and 5 compare LYG and LYL for high-  
245 and low-sensitivity scenarios. High-sensitivity scenarios are expected to yield higher LYG  
246 benefits than low-sensitivity scenarios, and the magnitude of this difference is higher for  
247 more intensive screening regimens. For 60-year-olds with a prior colonoscopy at age 50  
248 who experience a 18-month delay during the pandemic (scenario C60 | C 18m), the benefit  
249 of screening is 240 to 297 LYG per 1,000 individuals under a *High colonoscopy sensitivity*  
250 scenario, whereas it is 217 to 272 under a *Low colonoscopy sensitivity* scenario (defined in  
251 Supplementary Table 1).

252 Nevertheless, conditional on the sensitivity scenario, the effect of pandemic  
253 disruptions on LY lost is expected to be very similar for low-sensitivity scenarios. An 18-

254 month delay in colonoscopy screening is expected to result in a loss of 0 to 3 LY per 1,000  
255 individuals for 60-year-olds assuming high sensitivity, whereas it is expected to result in a  
256 loss of 0 to 4 LY per 1,000 individuals assuming low sensitivity.

257

258

## 259 **Discussion**

260 Model-based screening cost-effectiveness analyses present estimates under guideline-  
261 concordant scenarios, but there are many reasons why real-world screening will not  
262 follow guidelines. Chief amongst them in 2020, the COVID-19 pandemic severely disrupted  
263 screening. Under those conditions, disparities in health outcomes can arise if disruptions  
264 are unevenly distributed in the population.

265 Our results suggest that the COVID-19 pandemic will have an uneven effect on CRC  
266 outcomes depending on whether and how fast screening is resumed after the pandemic  
267 onset. Consider three cohorts with the same pre-pandemic screening regimen and  
268 behavior: 60-year-olds with a prior colonoscopy at age 50. Cohorts that experience short-  
269 term disruptions (e.g., 3-18 months) only experience a small loss of life due to short-term  
270 delays – up to 3 LY per 1,000 individuals Those who switch from colonoscopy to FIT  
271 screening are projected to experience a greater loss of life – from 9 to 11 to LY per 1,000  
272 individuals). If screening is only resumed at age 65 (e.g., age at Medicare enrollment) or  
273 abandoned, the loss of benefits from screening could be 3 to 11 LY per 1,000 individuals  
274 (scenario C60 | C@65). Lastly, discontinuing screening after the pandemic is projected to  
275 cause a loss of 106 to 124 LY per 1,000 individuals, a decrease of 36 to 51 percent in the  
276 benefit of screening (scenario C60 | U). These results imply that the pandemic will become  
277 a disparity-widening mechanism if it differentially affects screening access and or  
278 behavior across different population groups. These results also show that the pandemic is  
279 unlikely to generate any substantial effect on those whose screening is only interrupted  
280 momentarily.

281 These results highlight the potential implications of disruptions to preventative  
282 care due to loss of insurance following the pandemic. According to data from the Bureau

283 of Labor Statistics Current Population Survey, more dramatic declines in the number  
284 employed during the COVID-19 pandemic were seen in Black, Asian American and  
285 Hispanic groups.<sup>22</sup> Moreover, data from the US Census Household Pulse Survey suggests  
286 that Black and Hispanic workers were not only more likely to be unemployed but were  
287 also more likely to be without unemployment insurance.<sup>23</sup> These results provide important  
288 clinical insight on the projected impact of these populations which may guide future policy  
289 on the aftereffects of the pandemic. Those who were previously uninsured for long periods  
290 of time throughout the pandemic should be prioritized to resume timely CRC screening to  
291 mitigate the long-term effects postulated in these simulations.

292 These results also add to the growing evidence of the implications of delayed CRC  
293 care following the COVID-19 pandemic. A microsimulation study based on a Canadian  
294 population explored scenarios of differing screening delays and transition periods due to  
295 attenuated screening volumes and found that a 6-month delay in primary screening could  
296 increase CRC incidence by 2,200 cases and 960 more cancer deaths over a lifetime.<sup>24</sup> A  
297 microsimulation paper based on a Chilean population illustrated similar results with  
298 respect to CRC incidence and mortality due to the screening backlog and strained patient  
299 care during the pandemic.<sup>25</sup> Our results mirror these conclusions and provide new  
300 scenarios which consider the aftereffects of loss of healthcare insurance due to disparities  
301 magnified by the COVID-19 pandemic.

302

### 303 *Limitations*

304 This analysis presents a series of limitations. First, we do not present population-level  
305 estimates of reductions in benefits. While doing so could prove helpful, one would have to  
306 estimate how many people will be screened following each scenario we modeled. That  
307 would require individual-level data describing the distribution of delays and screening  
308 regimen switching in the population after the pandemic, which will not be available for  
309 many years. Instead of pursuing a population-level study, we conditioned our estimates  
310 on a discrete set of pre-specified disruption scenarios. This approach makes our study  
311 feasible but prevents us from making population-level predictions.

312           Second, the scenarios presented in this analysis represent only a subset of the real-  
313 world changes in screening due to the pandemic. Even in the absence of a pandemic,  
314 individuals may switch from colonoscopy to FIT, and return to colonoscopy screening. To  
315 keep this analysis tractable, we restrict the variations considered in this paper to one  
316 switch from colonoscopy to FIT. Further, we only consider changes in screening regimens  
317 immediately following the COVID-19 pandemic.

318           Third, this analysis only considers uncertainty stemming from structural  
319 differences between models and two scenarios of test characteristics and does not evaluate  
320 parameter or sampling uncertainty. Our estimates represent the expected value of  
321 estimates conditional on scenarios across an average-risk cohort drawn from the general  
322 US population. Finally, this analysis focuses on the effects of the pandemic on the primary  
323 measure of the benefit of CRC screening - life-years gained from screening. We do not  
324 present the effects of disruptions on other secondary measures that will likely be affected,  
325 such as cancer incidence and screening utilization.

326

## 327 **Conclusion**

328 This study quantified the potential effect of a set of disruptions to colonoscopy screening  
329 and demonstrated that unequal recovery of CRC screening following the pandemic will  
330 predictably widen disparities in CRC outcomes. The COVID-19 pandemic will severely  
331 reduce the benefits of CRC screening if it causes screening discontinuation or long-term  
332 (e.g., 5-year) delays. Short-term delays of 3-18 months and regime switching from  
333 colonoscopy to FIT tests are not expected to have significant consequences.

334

335

## 336 **Acknowledgements**

337 This research was supported by grant U01-CA253913 from the National Cancer Institute  
338 (NCI) as part of the Cancer Intervention and Surveillance Modeling Network (CISNET).  
339 Additional funding was obtained from the NIH/NCI Cancer Center Support Grant P30  
340 CA008748 (Zauber). This research used resources of the Argonne Leadership Computing  
341 Facility, which is a DOE Office of Science User Facility supported under Contract DE- AC02-  
342 06CH11357. We would like to thank the Argonne Leadership Computing Facility staff for  
343 their timely and critical support. This research was completed with resources provided by  
344 the Laboratory Computing Resource Center at Argonne National Laboratory. The content  
345 is solely the responsibility of the authors and does not necessarily represent the official  
346 views of the National Institutes of Health.

347

## 348 **Data Availability**

349 This is a computational study based on two independently developed simulation models.  
350 Simulation output data and code used to produce the figures and Supplementary Table 3  
351 in this paper are available at <https://github.com/c-rutter/unequal-recovery-covid-19>. Full  
352 documentation of CISNET models used to produce the results presented in this study can  
353 be found at <https://cisnet.cancer.gov/colorectal/profiles.html>. Interested researchers can  
354 contact authors directly for more insight into the CISNET models.

## 355 References

- 356 1. Johns Hopkins University & Medicine Coronavirus Resource Center.  
357 <https://coronavirus.jhu.edu/map.html>, 2022.
- 358 2. Gupta S, Shahidi N, Gilroy N, et al. Proposal for the return to routine endoscopy during  
359 the COVID-19 pandemic. *Gastrointest Endosc* 2020;92:735-742.
- 360 3. London JW, Fazio-Eynullayeva E, Palchuk MB, et al. Effects of the COVID-19 Pandemic  
361 on Cancer-Related Patient Encounters. *JCO Clinical Cancer Informatics* 2020:657-665.
- 362 4. Wilensky GR. The COVID-19 Pandemic and the US Health Care Workforce. *JAMA*  
363 *Health Forum* 2022;3:e220001-e220001.
- 364 5. Del Vecchio Blanco G, Calabrese E, Biancone L, et al. The impact of COVID-19  
365 pandemic in the colorectal cancer prevention. *Int J Colorectal Dis* 2020;35:1951-  
366 1954.
- 367 6. Ong MBH. EPIC EHR Data: Cancer Screenings Nosedive in 2021 Despite Easing of  
368 COVID Restrictions *The Cancer Letter*. Volume 47, 2021:3-7.
- 369 7. Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. *CA: A Cancer Journal for*  
370 *Clinicians* 2022;72:7-33.
- 371 8. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of  
372 cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions  
373 (risk factors, screening, and treatment) to reduce future rates. *Cancer* 2010;116:544-  
374 73.
- 375 9. Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term  
376 prevention of colorectal-cancer deaths. *N Engl J Med* 2012;366:687-96.
- 377 10. Knudsen AB, Rutter CM, Peterse EFP, et al. Colorectal Cancer Screening: An Updated  
378 Modeling Study for the US Preventive Services Task Force. *JAMA* 2021;325:1998-  
379 2011.
- 380 11. Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer  
381 screening. *Epidemiol Rev* 2011;33:88-100.
- 382 12. Force UPST. Screening for Colorectal Cancer: US Preventive Services Task Force  
383 Recommendation Statement. *JAMA* 2021;325:1965-1977.
- 384 13. Shapiro JA, Soman AV, Berkowitz Z, et al. Screening for Colorectal Cancer in the United  
385 States: Correlates and Time Trends by Type of Test. *Cancer Epidemiology,*  
386 *Biomarkers & Prevention* 2021;30:1554-1565.



- 387 14. Marcondes FO, Cheng D, Warner ET, et al. The trajectory of racial/ethnic disparities  
388 in the use of cancer screening before and during the COVID-19 pandemic: A large U.S.  
389 academic center analysis. *Prev Med* 2021;151:106640.
- 390 15. Fedewa SA, Yabroff KR, Bandi P, et al. Unemployment and cancer screening: Baseline  
391 estimates to inform health care delivery in the context of COVID-19 economic  
392 distress. *Cancer* 2022;128:737-745.
- 393 16. Loeve F, Boer R, van Oortmarssen GJ, et al. The MISCAN-COLON simulation model for  
394 the evaluation of colorectal cancer screening. *Comput Biomed Res* 1999;32:13-33.
- 395 17. Rutter CM, Ozik J, DeYoreo M, et al. Microsimulation model calibration using  
396 incremental mixture approximate Bayesian computation. *The Annals of Applied  
397 Statistics* 2019;13:2189-2212, 24.
- 398 18. van Hees F, Habbema JD, Meester RG, et al. Should colorectal cancer screening be  
399 considered in elderly persons without previous screening? A cost-effectiveness  
400 analysis. *Ann Intern Med* 2014;160:750-9.
- 401 19. Knudsen AB, Zauber AG, Rutter CM, et al. Estimation of Benefits, Burden, and Harms  
402 of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive  
403 Services Task Force. *Jama* 2016;315:2595-609.
- 404 20. Gupta S, Lieberman D. Screening and Surveillance Colonoscopy and COVID-19:  
405 Avoiding More Casualties. *Gastroenterology* 2020;159:1205-1208.
- 406 21. Choy AM, Lebwohl B, Krigel A. Impact of social determinants of health on colorectal  
407 cancer screening and surveillance in the COVID reopening phase. *Eur J Gastroenterol  
408 Hepatol* 2022;34:739-743.
- 409 22. Gemelas J, Davison J, Keltner C, et al. Inequities in Employment by Race, Ethnicity, and  
410 Sector During COVID-19. *J Racial Ethn Health Disparities* 2022;9:350-355.
- 411 23. Mar D, Ong P, Larson T, et al. Racial and ethnic disparities in who receives  
412 unemployment benefits during COVID-19. *SN Bus Econ* 2022;2:102.
- 413 24. Yong JH, Mainprize JG, Yaffe MJ, et al. The impact of episodic screening interruption:  
414 COVID-19 and population-based cancer screening in Canada. *Journal of Medical  
415 Screening* 2021;28:100-107.
- 416 25. Ward ZJ, Walbaum M, Walbaum B, et al. Estimating the impact of the COVID-19  
417 pandemic on diagnosis and survival of five cancers in Chile from 2020 to 2030: a  
418 simulation-based analysis. *The Lancet Oncology* 2021;22:1427-1437.
- 419 26. Lin JS, Perdue LA, Henrikson NB, et al. Screening for Colorectal Cancer: Updated  
420 Evidence Report and Systematic Review for the US Preventive Services Task Force.  
421 *Jama* 2021;325:1978-1997.

- 422 27. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, et al. Evaluating test strategies for  
423 colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task  
424 Force. *Ann Intern Med* 2008;149:659-69.
- 425 28. Rutter CM, Nascimento de Lima P, Lee JK, et al. Too Good to Be True? Evaluation of  
426 Colonoscopy Sensitivity Assumptions Used in Policy Models. *Cancer Epidemiol*  
427 *Biomarkers Prev* 2022;31:775-782.  
428

429 **Supplementary Appendix**

430

431 This supplementary appendix presents details about the computing environment used in  
432 the study, supplementary figures, and tables.

433

434 **Computing Environment**

435 All experiments were run on the Argonne Leadership Computing Facility's Theta  
436 supercomputer, and on Bebop, an HPC cluster managed by the Laboratory Computing  
437 Resource Center at Argonne National Laboratory, using the EMEWS workflow framework.  
438 Theta is a Cray XC40 with 4,392 compute nodes, each with an Intel KNL 7230 (Xeon Phi),  
439 aggregating 11.7 petaflops in total. Each node has 64 compute cores with access to 16 GB  
440 of high-bandwidth in-package memory, 192 GB of DDR4 RAM, and 128 GB of SSD. Bebop  
441 has 1024 nodes comprised of 672 Intel Broadwell processors with 36 cores per node and  
442 128 GB of RAM and 372 Intel Knights Landing processors with 64 cores per node and 96  
443 GB of RAM.

444

445


446

447

448

449

450 **Supplementary Figure 1. Estimated loss of life in minor disruption scenarios**




451

452 *Notes:* Each dot represents the estimated life-years lost per 1000 individuals or life-days lost from one model.

453 Results are ordered from highest to lowest reduction in benefit induced by the pandemic

454

455 **Supplementary Figure 2.** Estimated loss of life under low sensitivity assumptions




456

457 *Notes:* Each dot represents the estimated life-years lost per 1000 individuals or life-days lost from one model.

458 Results are ordered from highest to lowest reduction in benefit induced by the pandemic.

459 **Supplementary Figure 3.** Estimated loss of life in minor disruption scenarios and low  
 460 sensitivity assumptions



461  
 462 *Notes:* Each dot represents the estimated life-years lost per 1000 individuals or life-days lost from one model.  
 463 Results are ordered from highest to lowest reduction in benefit induced by the pandemic.  
 464


465  
 466

467

468

469

**Supplementary Figure 4.** Life-years gained in high- vs. low-sensitivity scenarios



470

471

472

473

474


475

476

477

*Notes:* Each dot represents one scenario considered in this study. The horizontal axis displays the number of Life-years gained (LYG) estimated in that scenario under a high colonoscopy sensitivity scenario. The vertical axis shows the results for the same cohort under a low colonoscopy sensitivity scenario. If Sensitivity did not affect the estimate, then all points would be on top of a 45-degree line. Different colors represent CRCSPIN and MISCAN models.

478 **Supplementary Figure 5. Life-years lost in high- vs. low-sensitivity scenarios**



479  
480 *Notes:* Each dot represents one scenario considered in this study. The horizontal axis displays the number of  
481 Life-years lost due to disruptions (LYL) estimated in that scenario under a high colonoscopy sensitivity  
482 scenario. The vertical axis shows the results for the same cohort under a low colonoscopy sensitivity scenario.  
483 If Sensitivity did not affect the estimate, then all points would be on top of a 45-degree line. Different colors  
484 represent CRCSPIN and MISCAN models.

485  
486  
487



488 **Test Characteristics**

489  
 490 This appendix specifies sensitivity and specificity assumptions underlying colonoscopy  
 491 and FIT exams evaluated in this study. Supplementary Table 2 specifies per-lesion  
 492 sensitivity and specificity assumptions for the two scenarios evaluated in this paper.

493

494 **Supplementary Table 1. Per lesion test sensitivity and specificity**

Test	Sensitivity*				Specificity
	Adenoma 1-5mm	Adenoma 6-9mm	Adenoma ≥10mm	Preclinical cancer	**
Colonoscopy, high sensitivity <sup>†</sup>	0.75	0.85	0.95	0.95	0.86
Colonoscopy, low sensitivity <sup>‡</sup>	0.55	0.70	0.90	0.95	0.86
FIT <sup>§</sup>					
MISCAN	0.00	0.114	0.159	0.62565/0.886	0.97
CRC-SPIN	0.05	0.15	0.22	*0.74	0.97

495 Notes: This table presents the assumed test characteristics. We simulated two colonoscopy sensitivity scenarios  
 496 seeking to represent a range of colonoscopy sensitivity of gastroenterologists in the US.

497 \*Sensitivity is for lesions within reach of the scope. We assume the same test characteristics for follow-up and  
 498 surveillance colonoscopy as for screening colonoscopy.

499 \*\*For FIT tests, the lack of specificity reflects detection of bleeding from other causes. We assume other-cause  
 500 bleeding is independent of adenoma status. For colonoscopy, the lack of specificity reflects detection of non-  
 501 adenomatous lesions, but specificity is handled in post-processing in cost-effectiveness analyses. Since this  
 502 study does not consider burden outcomes, specificity is not considered in this paper. Specificity values were  
 503 obtained from Lin et al.<sup>26</sup>

504 <sup>†</sup> Baseline scenarios used in Zauber et al.<sup>27</sup>

505 <sup>‡</sup> In line with low-sensitivity scenarios compatible with Rutter et al.<sup>28</sup>

506 <sup>§</sup> CRC-SPIN uses per-person test sensitivity for stool-based tests that are based on the size of the most advanced  
 507 lesion. To account for the likelihood that a person with multiple adenomas is more likely than a person with  
 508 only one to have a positive stool test, MISCAN uses lesion-based sensitivities instead of person-based  
 509 sensitivities. Lesion-based sensitivities were derived by calibrating the person-based sensitivities to the  
 510 number of people having one or more small/medium/large adenomas or cancers detected by stool-based  
 511 testing with diagnostic colonoscopy, divided by those having one or more small/medium/large adenomas or  
 512 cancers detected by colonoscopy screening.

513

## 514 **CRC Surveillance**

515 We assume that individuals with an adenoma detected undergo colonoscopic surveillance  
516 according to the Multi-Society Task Force (MSTF) guidelines. These guidelines provide  
517 intervals for surveillance based on baseline findings and findings at the first surveillance  
518 colonoscopy. We assume the intervals provided can be more generally expressed as the  
519 intervals based on the most recent colonoscopy (“first most recent colonoscopy”) and the  
520 colonoscopy prior to that (“second most-recent colonoscopy”). In situations where the MSTF  
521 provided a range rather than a single interval, we assumed that the shortest interval would be  
522 used in routine practice. The resulting intervals are shown in **Supplementary Table 3**.

523

524 We assume that persons in whom adenoma(s) have been detected remain on  
525 surveillance until age 85, provided that no adenomas are detected at the last surveillance  
526 colonoscopy. If adenomas are detected, then surveillance continues according to the clinical  
527 findings at the last colonoscopy until the person has a colonoscopy with no adenomas detected.  
528 For example, if a person has a surveillance colonoscopy at age 83 and no adenomas are  
529 detected at this exam or the exam before this one, they would be recommended to have their  
530 next surveillance at age 93. Age 93 is after the surveillance stopping age of 85 and the exam  
531 prior to age 85 was negative, so they will not have any more surveillance colonoscopies after  
532 age 83. However, if the exam at age 83 instead detected 1-2 small adenomas, they would come  
533 back for their surveillance colonoscopy at age 90, because adenomas were detected at the exam  
534 at age 83. As noted in the section on adherence above, in the primary analyses, we assume  
535 persons with adenoma findings are perfectly adherent with the surveillance colonoscopy  
536 schedules shown in **Supplementary Table 3**.

537

538

**Supplementary Table 2. CRC Surveillance Intervals**

<b>Finding at second-most recent colonoscopy**†</b>	<b>Finding at first-most recent colonoscopy**†</b>	<b>Interval‡ to next colonoscopy, y</b>
No prior colonoscopy	Normal colonoscopy	See note below§
	1-2 adenomas <10 mm	7
	3-4 adenomas <10 mm	3
	10 adenomas <10 mm or any adenoma ≥10 mm	3
	> 10 adenomas	1
Normal colonoscopy	Normal colonoscopy	10
	1-2 adenomas <10 mm	7
	3-4 adenomas <10 mm	3
	5-10 adenomas <10 mm or any adenoma ≥10 mm	3
	> 10 adenomas	1
1-2 adenomas <10 mm	Normal colonoscopy	10
	1-2 adenomas <10 mm	7
	3-4 adenomas <10 mm	3
	5-10 adenomas <10 mm or any adenoma ≥10 mm	3
	> 10 adenomas	1
3-4 adenomas <10 mm	Normal colonoscopy	10
	1-2 adenomas <10 mm	7
	3-4 adenomas <10 mm	3
	5-10 adenomas <10 mm or any adenoma ≥10 mm	3
	> 10 adenomas	1
5-10 adenomas <10 mm or any adenoma ≥10 mm	Normal colonoscopy	5
	1-2 adenomas <10 mm	5
	3-4 adenomas <10 mm	3
	5-10 adenomas <10 mm or any adenoma ≥10 mm	3
	> 10 adenomas	1
> 10 adenomas of any size	Normal colonoscopy	5
	1-2 adenomas <10 mm	5
	3-4 adenomas <10 mm	3
	5-10 adenomas <10 mm or any adenoma ≥10 mm	3
	>10 adenomas	1

539  
540  
541  
542  
543  
544  
545  
546  
547

\* A normal colonoscopy is one in which no adenomas, SSPs (not currently simulated), or CRC is detected.  
 † This table omits the case where CRC is detected at a screening, diagnostic, or surveillance colonoscopy because the CISNET CRC models do not simulate detailed events following CRC diagnosis.  
 ‡ The Multi-Society Task Force provides a range for some intervals (e.g., the interval for 3-4 adenomas <10 mm is 3-5 years). In such cases, we selected the shortest intervals provided.  
 § A person whose first screening or diagnostic colonoscopy is normal does not enter surveillance but instead resumes screening with the original modality 10 years after the normal colonoscopy. The exception to the 10-year waiting period is when the first colonoscopy is a screening colonoscopy with an x-year interval, where x >10. In that case, the next colonoscopy is in x years.

**Supplementary Table 3.** Lifetime estimates of CRC outcomes

Colonoscopy Sensitivity	Scenario	Model	Life-Years (LY)	LY No Screening	LY No Disruptions	LYG No Disruptions	LYG Screening	LY Lost Disruptions	% LYG Loss
High	U50   C3m	CRCSPIN	31892	31595	31893	299	297	2	1
		MISCAN	31424	31156	31428	272	269	3	1
	U50   C9m	CRCSPIN	31890	31595	31893	299	295	3	1
		MISCAN	31423	31156	31428	272	268	5	2
	U50   C18m	CRCSPIN	31886	31595	31893	299	291	7	2
		MISCAN	31421	31156	31428	272	266	6	2
	U50   C@65	CRCSPIN	31766	31595	31893	299	172	127	43
		MISCAN	31324	31156	31428	272	168	104	38
	U50   F3m	CRCSPIN	31865	31595	31866	271	270	1	0
		MISCAN	31414	31156	31416	260	259	1	1
	U50   F9m	CRCSPIN	31862	31595	31866	271	268	3	1
		MISCAN	31413	31156	31416	260	258	2	1
	U50   F18m	CRCSPIN	31858	31595	31866	271	264	7	3
		MISCAN	31411	31156	31416	260	256	5	2
	U60   C3m	CRCSPIN	23440	23218	23438	220	222	-3	-1
		MISCAN	23139	22950	23144	194	189	5	3
	U60   C9m	CRCSPIN	23435	23218	23438	220	218	2	1
		MISCAN	23136	22950	23144	194	186	8	4
	U60   C18m	CRCSPIN	23428	23218	23438	220	210	9	4
		MISCAN	23131	22950	23144	194	180	14	7
U60   C@65	CRCSPIN	23393	23218	23438	220	175	45	20	
	MISCAN	23103	22950	23144	194	152	42	21	
U60   F3m	CRCSPIN	23410	23218	23408	190	192	-2	-1	
	MISCAN	23123	22950	23126	176	173	3	1	
U60   F9m	CRCSPIN	23406	23218	23408	190	188	2	1	

Colonoscopy Sensitivity	Scenario	Model	Life-Years (LY)	LY No Screening	LY No Disruptions	LYG No Disruptions	LYG Screening	LY Lost Disruptions	% LYG Loss
U60   F18m		MISCAN	23120	22950	23126	176	170	6	3
		CRCSPIN	23400	23218	23408	190	182	8	4
C60   C3m		MISCAN	23115	22950	23126	176	165	11	6
		CRCSPIN	23483	23185	23482	298	298	0	0
C60   C9m		MISCAN	23163	22924	23165	241	239	2	1
		CRCSPIN	23483	23185	23482	298	298	0	0
C60   C18m		MISCAN	23163	22924	23165	241	239	2	1
		CRCSPIN	23482	23185	23482	298	297	0	0
C60   F3m		MISCAN	23161	22924	23165	241	238	3	1
		CRCSPIN	23474	23185	23483	298	289	9	3
C60   F9m		MISCAN	23155	22924	23165	241	232	10	4
		CRCSPIN	23473	23185	23483	298	288	9	3
C60   F18m		MISCAN	23155	22924	23165	241	232	9	4
		CRCSPIN	23473	23185	23482	298	288	9	3
C60   C@65		MISCAN	23154	22923	23165	241	230	11	4
		CRCSPIN	23479	23185	23483	298	294	3	1
C60   U		MISCAN	23154	22924	23165	241	230	11	5
		CRCSPIN	23377	23185	23483	298	192	106	36
F60   F3m		MISCAN	23041	22924	23165	241	117	124	51
		CRCSPIN	23457	23190	23460	270	267	3	1
F60   F9m		MISCAN	23157	22925	23157	231	231	0	0
		CRCSPIN	23456	23189	23460	270	267	3	1
F60   F18m		MISCAN	23156	22925	23156	231	231	0	0
		CRCSPIN	23454	23189	23460	270	265	5	2
F60   U		MISCAN	23156	22925	23157	231	231	1	0
		CRCSPIN	23349	23189	23460	270	160	111	41

Colonoscopy Sensitivity	Scenario	Model	Life-Years (LY)	LY No Screening	LY No Disruptions	LYG No Disruptions	LYG Screening	LY Lost Disruptions	% LYG Loss
f60   F3m		MISCAN	23064	22925	23156	231	139	92	40
		CRCSPIN	23440	23194	23442	247	245	2	1
f60   F9m		MISCAN	23145	22930	23147	217	215	2	1
		CRCSPIN	23438	23194	23442	247	244	4	1
f60   F18m		MISCAN	23145	22931	23147	217	214	3	1
		CRCSPIN	23436	23194	23442	247	241	6	3
f60   U		MISCAN	23143	22931	23147	217	212	5	2
		CRCSPIN	23299	23194	23442	247	105	142	58
		MISCAN	22998	22930	23147	217	68	149	69
U70   C3m		CRCSPIN	15849	15725	15851	126	124	3	2
		MISCAN	15550	15444	15559	115	106	9	8
U70   C9m		CRCSPIN	15843	15725	15851	126	118	8	6
		MISCAN	15546	15444	15559	115	101	14	12
U70   C18m		CRCSPIN	15836	15725	15851	126	111	15	12
		MISCAN	15539	15444	15559	115	95	20	18
U70   C@75		CRCSPIN	15803	15725	15851	126	78	49	39
		MISCAN	15509	15444	15559	115	65	50	43
U70   F3m		CRCSPIN	15817	15725	15819	94	92	2	2
		MISCAN	15527	15444	15534	90	83	7	8
U70   F9m		CRCSPIN	15814	15725	15819	94	88	5	6
		MISCAN	15524	15444	15534	90	80	10	11
U70   F18m		CRCSPIN	15808	15725	15819	94	83	11	12
		MISCAN	15519	15444	15534	90	75	16	17
C70   C3m		CRCSPIN	15905	15621	15905	284	284	0	0
		MISCAN	15596	15366	15597	231	230	1	0
C70   C9m		CRCSPIN	15905	15621	15905	284	284	0	0

Colonoscopy Sensitivity	Scenario	Model	Life-Years (LY)	LY No Screening	LY No Disruptions	LYG No Disruptions	LYG Screening	LY Lost Disruptions	% LYG Loss
	C70   C18m	MISCAN	15596	15366	15597	231	230	1	0
		CRCSPIN	15905	15621	15905	284	284	0	0
	C70   C@75	MISCAN	15595	15366	15597	231	229	2	1
		CRCSPIN	15905	15621	15905	284	284	0	0
	C70   F3m	MISCAN	15592	15366	15597	231	226	5	2
		CRCSPIN	15900	15621	15905	284	279	5	2
	C70   F9m	MISCAN	15591	15366	15597	231	225	6	3
		CRCSPIN	15901	15621	15905	284	280	4	1
	C70   F18m	MISCAN	15590	15366	15597	231	224	7	3
		CRCSPIN	15901	15621	15905	284	280	4	2
	C70   U	MISCAN	15590	15366	15597	231	224	7	3
		CRCSPIN	15867	15621	15905	284	246	38	13
	F70   F3m	MISCAN	15515	15372	15603	231	144	87	38
		CRCSPIN	15888	15631	15888	257	257	0	0
	F70   F9m	MISCAN	15588	15367	15588	222	221	0	0
		CRCSPIN	15888	15631	15889	257	257	1	0
	F70   F18m	MISCAN	15588	15367	15589	222	221	1	0
		CRCSPIN	15888	15632	15889	257	256	1	0
	F70   U	MISCAN	15588	15367	15588	222	221	0	0
		CRCSPIN	15855	15631	15888	257	224	33	13
Low	U50   C3m	MISCAN	15559	15367	15588	222	192	29	13
		CRCSPIN	31867	31595	31867	273	273	0	0
	U50   C9m	MISCAN	31401	31156	31405	249	246	3	1
		CRCSPIN	31866	31595	31867	273	271	2	1
	U50   C18m	MISCAN	31400	31156	31405	249	245	5	2
		CRCSPIN	31861	31595	31867	273	267	6	2

Colonoscopy Sensitivity	Scenario	Model	Life-Years (LY)	LY No Screening	LY No Disruptions	LYG No Disruptions	LYG Screening	LY Lost Disruptions	% LYG Loss
	U50   C@65	MISCAN	31398	31156	31405	249	242	7	3
		CRCSPIN	31751	31595	31867	273	156	117	43
	U50   F3m	MISCAN	31311	31156	31405	249	155	94	38
		CRCSPIN	31843	31595	31843	249	248	0	0
	U50   F9m	MISCAN	31397	31156	31398	243	242	1	1
		CRCSPIN	31841	31595	31843	249	246	2	1
	U50   F18m	MISCAN	31396	31156	31398	243	240	3	1
		CRCSPIN	31837	31595	31843	249	242	6	2
	U60   C3m	MISCAN	31394	31156	31398	243	238	5	2
		CRCSPIN	23420	23218	23418	200	202	-2	-1
	U60   C9m	MISCAN	23124	22950	23129	178	173	5	3
		CRCSPIN	23416	23218	23418	200	198	2	1
	U60   C18m	MISCAN	23121	22950	23129	178	171	8	4
		CRCSPIN	23409	23218	23418	200	191	9	4
	U60   C@65	MISCAN	23116	22950	23129	178	166	13	7
		CRCSPIN	23377	23218	23418	200	159	41	20
	U60   F3m	MISCAN	23091	22950	23129	178	141	37	21
		CRCSPIN	23394	23218	23392	174	176	-2	-1
	U60   F9m	MISCAN	23112	22950	23116	165	162	3	2
		CRCSPIN	23390	23218	23392	174	172	2	1
	U60   F18m	MISCAN	23110	22950	23116	165	160	6	3
		CRCSPIN	23385	23218	23392	174	167	7	4
	C60   C3m	MISCAN	23105	22950	23116	165	155	11	6
		CRCSPIN	23460	23188	23460	272	273	0	0
C60   C9m	MISCAN	23145	22926	23148	221	219	3	1	
	CRCSPIN	23460	23188	23460	272	272	1	0	
C60   C18m	MISCAN	23144	22926	23147	221	218	3	1	
	CRCSPIN	23459	23188	23460	272	271	1	0	



Colonoscopy Sensitivity	Scenario	Model	Life-Years (LY)	LY No Screening	LY No Disruptions	LYG No Disruptions	LYG Screening	LY Lost Disruptions	% LYG Loss
C60   F3m		MISCAN	23143	22926	23147	221	217	4	2
		CRCSPIN	23451	23188	23460	272	263	9	3
C60   F9m		MISCAN	23139	22926	23147	221	213	8	4
		CRCSPIN	23451	23188	23460	272	263	9	3
C60   F18m		MISCAN	23139	22926	23147	221	213	8	4
		CRCSPIN	23451	23188	23460	272	263	9	3
C60   C@65		MISCAN	23138	22926	23147	221	212	9	4
		CRCSPIN	23455	23188	23460	272	267	5	2
C60   U		MISCAN	23134	22926	23148	221	208	14	6
		CRCSPIN	23352	23187	23460	272	164	108	40
F60   F3m		MISCAN	23023	22926	23148	221	97	124	56
		CRCSPIN	23434	23191	23438	248	244	4	2
F60   F9m		MISCAN	23142	22926	23142	216	216	0	0
		CRCSPIN	23435	23191	23438	248	245	3	1
F60   F18m		MISCAN	23142	22926	23142	216	215	1	0
		CRCSPIN	23432	23191	23439	248	241	6	3
F60   U		MISCAN	23141	22926	23142	216	215	1	0
		CRCSPIN	23329	23191	23438	248	139	109	44
f60   F3m		MISCAN	23052	22926	23142	216	125	91	42
		CRCSPIN	23419	23195	23422	227	224	3	1
f60   F9m		MISCAN	23133	22931	23135	204	202	2	1
		CRCSPIN	23418	23195	23422	227	223	4	2
f60   F18m		MISCAN	23132	22931	23135	204	201	2	1
		CRCSPIN	23416	23195	23422	227	221	6	3
f60   U		MISCAN	23130	22931	23135	204	199	4	2
		CRCSPIN	23288	23195	23422	227	92	135	59
		MISCAN	22993	22931	23135	204	62	142	70
U70   C3m		CRCSPIN	15835	15725	15837	112	110	2	2

Colonoscopy Sensitivity	Scenario	Model	Life-Years (LY)	LY No Screening	LY No Disruptions	LYG No Disruptions	LYG Screening	LY Lost Disruptions	% LYG Loss
U70   C9m		MISCAN	15541	15444	15550	105	97	9	8
		CRCSPIN	15831	15725	15837	112	106	6	6
U70   C18m		MISCAN	15537	15444	15550	105	93	13	12
		CRCSPIN	15824	15725	15837	112	99	13	12
U70   C@75		MISCAN	15531	15444	15550	105	87	19	18
		CRCSPIN	15795	15725	15837	112	70	43	38
U70   F3m		MISCAN	15504	15444	15550	105	60	45	43
		CRCSPIN	15809	15725	15810	85	84	1	1
U70   F9m		MISCAN	15523	15444	15530	86	79	7	8
		CRCSPIN	15806	15725	15810	85	81	4	5
U70   F18m		MISCAN	15520	15444	15530	86	76	10	12
		CRCSPIN	15801	15725	15810	85	76	9	11
C70   C3m		MISCAN	15515	15444	15530	86	71	15	17
		CRCSPIN	15889	15629	15889	260	260	0	0
C70   C9m		MISCAN	15584	15373	15585	212	211	1	1
		CRCSPIN	15890	15629	15889	260	261	-1	0
C70   C18m		MISCAN	15583	15373	15585	212	210	2	1
		CRCSPIN	15889	15629	15889	260	260	0	0
C70   C@75		MISCAN	15583	15373	15585	212	210	2	1
		CRCSPIN	15889	15629	15889	260	260	0	0
C70   F3m		MISCAN	15578	15373	15585	212	205	7	4
		CRCSPIN	15885	15629	15889	260	255	5	2
C70   F9m		MISCAN	15579	15373	15585	212	206	6	3
		CRCSPIN	15886	15629	15889	260	256	4	1
C70   F18m		MISCAN	15578	15373	15586	212	205	7	3
		CRCSPIN	15885	15629	15889	260	255	4	2
C70   U		MISCAN	15578	15373	15585	212	205	7	3
		CRCSPIN	15850	15629	15889	260	220	40	15

Colonoscopy Sensitivity	Scenario	Model	Life-Years (LY)	LY No Screening	LY No Disruptions	LYG No Disruptions	LYG Screening	LY Lost Disruptions	% LYG Loss
	F70   F3m	MISCAN	15505	15378	15591	212	127	85	40
		CRCSPIN	15871	15638	15872	234	234	0	0
	F70   F9m	MISCAN	15577	15372	15577	206	206	0	0
		CRCSPIN	15872	15638	15872	234	233	1	0
	F70   F18m	MISCAN	15578	15372	15578	206	206	0	0
		CRCSPIN	15871	15638	15872	234	233	1	0
	F70   U	MISCAN	15577	15372	15577	206	206	0	0
		CRCSPIN	15839	15638	15872	234	201	33	14
		MISCAN	15548	15372	15577	206	177	29	14

549  
550  
551  
552  
553  
554  
555  
556  
557

*Notes:* Outcomes calculated over the lifetime of a cohort of 1000 average-risk, CRC-free individuals with age at pandemic defined in the scenario description. The scenario column describes colorectal cancer screening disruption scenarios, as presented in Table 1. The Life-years (LY) column presents life-years after 2020 under the specified scenarios. LY No Screening is a counterfactual scenario under which no CRC screening is performed. LY No Disruptions refers to a scenario of no pandemic-induced disruptions and no delays, and no switching of screening regimen. Life-years gained (LYG) under no disruptions refers to the number of life-years gained had no pandemic-induced disruptions happened. LYG Screening refers to the expected life-years gained under the specified scenario. LY Lost Pandemic refers to the number of life-years lost due to disruptions, and Perc LYG Loss refers to the percent reduction in LYG due to the pandemic relative to the no-disruption scenario. All values refer to cohort-level estimates – that is, the expected life-years of an average-risk person.


# Life-days lost per person

- CRCSPIN
- MISCAN


**50 year-olds**



**60 year-olds**




**70 year-olds**



# Life-years lost per 1000 individuals

Scenario


LY Lost under Low-Sensitivity Assumptions



● CRCSPIN  
● MISCAN

LY Lost under High-Sensitivity Assumptions

**LYG under Low-Sensitivity Assumptions**



**LYG under High-Sensitivity Assumptions**

# Life-days lost per person

- CRCSPIN
- MISCAN

Scenario

U50 | C9m

U50 | C3m

U50 | F9m

U50 | F3m

50 year-olds

U60 | C3m

U60 | F3m

f60 | F9m

f60 | F3m

60 year-olds

F60 | F3m

F60 | F9m

C60 | C18m

C60 | C9m

C60 | C3m

F70 | F18m

F70 | F9m




F70 | F3m

C70 | C18m


C70 | C9m

C70 | C3m

70 year-olds



Life-years lost per 1000 individuals






# Life-days lost per person

-1                      0                      1                      2


● CRCSPIN  
● MISCAN

U50 | C9m  
U50 | F9m  
U50 | C3m  
U50 | F3m




**50 year-olds**

U60 | C3m  
U60 | F3m  
f60 | F9m  
f60 | F3m  
F60 | F18m  
F60 | F3m  
F60 | F9m  
C60 | C18m  
C60 | C9m  
C60 | C3m



**60 year-olds**

F70 | F18m  
F70 | F9m  
F70 | F3m  
C70 | C@75  
C70 | C18m  
C70 | C9m  
C70 | C3m



**70 year-olds**

Scenario

Life-years lost per 1000 individuals